BISSAU, Guinea-Bissau
Guinea-Bissau has stopped a controversial United States-funded hepatitis B vaccine trial involving thousands of newborn babies after mounting international criticism, ethical concerns and questions over government authorisation. The proposed study, backed by $1.6 million in funding from the US Centers for Disease Control and Prevention (CDC), was designed to investigate the broader health effects of administering hepatitis B vaccines immediately after birth.
Researchers from the Bandim Health Project, affiliated with the University of Southern Denmark, planned to enrol approximately 14,000 newborns.
Half would receive the vaccine at birth, while the remaining babies would receive it at six weeks, following Guinea-Bissau’s existing vaccination schedule.
However, the arrangement sparked widespread condemnation from medical professionals and international health organisations, who warned that delaying vaccination could expose vulnerable infants to preventable infection.
The World Health Organization (WHO) criticised the study’s design, arguing that withholding early protection against hepatitis B raised serious ethical and scientific concerns.
Hepatitis B is a potentially life-threatening viral infection affecting the liver. Babies infected during childbirth face particularly high risks of developing chronic disease, which can eventually cause cirrhosis, liver failure or cancer.
The WHO recommends vaccination within 24 hours of birth and says the intervention can prevent 70 to 95 percent of mother-to-child transmission cases.
Guinea-Bissau, where hepatitis B remains widespread, plans to introduce universal birth-dose vaccination by 2028.
Researchers defended their proposal, arguing that babies assigned to receive the vaccine at six weeks would still follow existing national guidelines.
They maintained that the study could provide valuable evidence about vaccination’s wider health effects before the country’s planned immunisation expansion.
Nevertheless, Guinea-Bissau’s Health Minister, Quinhin Nantote, denied reports that the government had authorised the trial.
On October 19, judicial police searched the Bandim research facilities in Bissau and seized vaccine supplies as authorities examined their origins, handling and compliance with national regulations.
Days later, researcher Frederik Schaltz-Buchholzer confirmed that the project would not proceed because the necessary government approval had not been secured.
Researchers said the trial had not begun and no vaccines had been administered under the study.
The controversy has renewed debate over medical research ethics, foreign-funded health programmes and the protection of vulnerable populations in developing countries.
Public health experts are now urging greater investment in routine immunisation, maternal screening and reliable vaccine distribution.
For Guinea-Bissau, the immediate challenge remains ensuring that newborns receive timely protection against hepatitis B while maintaining public confidence in scientific research and national healthcare institutions.




















